Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for Elagolix
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Fibroids
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Trial Timeline
Dec 22, 2015 → Dec 12, 2018
NCT ID
NCT02654054About Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for Elagolix
Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for Elagolix is a phase 3 stage product being developed by AbbVie for Uterine Fibroids. The current trial status is completed. This product is registered under clinical trial identifier NCT02654054. Target conditions include Uterine Fibroids, Heavy Menstrual Bleeding.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02691494 | Phase 3 | Completed |
| NCT02654054 | Phase 3 | Completed |
Competing Products
20 competing products in Uterine Fibroids